Apnea: Clinical Trials

107 trials for Apnea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

107 completed. 107 Phase 2, 19 Phase 1, 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2107Completed 107
Phase 119Completed 19
Phase 315Completed 15

Follow Apnea: new trials by email Literature Review of Apnea trials Research Report on Apnea

Trials (filtered) newest first · largest first

All 107 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
Lorundrostat, Placebo - Obstructive Sleep Apnea, Hypertension
Phase 2CompletedMineralys Therapeutics Inc.482025-02-282026-08-21
Study That Tests AD109 in Patients Taking GLP-1 Drugs
AD109 - OSA
Phase 2CompletedApnimed402024-05-202025-02-19
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
IHL-42X Low Dose, IHL-42X High Dose, Placebo - Obstructive Sleep Apnea
Phase 2 / Phase 3CompletedIncannex Healthcare Ltd1212024-05-022026-07-27
Managing Opioid Related Sleep Apnea With Acetazolamide
Acetazolamide, Placebo - Sleep-Disordered Breathing, Obstructive Sleep Apnea
Phase 2CompletedUniversity of California, San Diego392023-10-182026-03-10
Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)
Eszopiclone 2 mg, Placebo - Obstructive Sleep Apnea
Phase 2CompletedUniversity of California, San Diego422023-08-312025-11-25
AD816 Crossover Study
Period A, Period B, Period C - OSA, Obstructive Sleep Apnea
Phase 2CompletedApnimed252023-04-282023-11-15
Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold
Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1, Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2, Placebo Day 1 - OSA
Phase 1 / Phase 2CompletedChulalongkorn University102023-02-012025-09-17
Acetazolamide on REM OSA
Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea
Phase 1 / Phase 2CompletedBrigham and Women's Hospital112023-01-302026-01-20
Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health
Acetazolamide, Placebo, Continuous Positive Airway Pressure - Obstructive Sleep Apnea
Phase 2CompletedUniversity of California, San Diego542022-12-022025-11-25
Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome
AD981, Placebo - Obesity Hypoventilation Syndrome (OHS)
Phase 2CompletedIstituto Auxologico Italiano152022-06-212025-02-27
Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea
Quetiapine 50 MG, Placebo - Sleep Apnea, Obstructive
Phase 2CompletedFlinders University152022-05-252023-07-06
Pediatric Pain Optimization After Tonsillectomy
Fentanyl/Hydromorphone, Methadone - Obstructive Sleep Apnea, Tonsillitis
Phase 2CompletedDuke University662022-04-082024-10-17
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
AD109, AD504, Atomoxetine Hydrochloride - OSA - Obstructive Sleep Apnea
Phase 2CompletedApnimed2942021-11-292026-08-12
Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA)
Sulthiame - Obstructive Sleep Apnea
Phase 2CompletedDesitin Arzneimittel GmbH2982021-11-232023-11-29
Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)
Dosing 1: Atomoxetine, AD313 - Obstructive Sleep Apnea
Phase 1 / Phase 2CompletedApnimed152021-10-192023-04-07
Prospective Randomized Trial of CPAP for SDB in Patients Who Use Opioids
Positive Airway Pressure (PAP) - Sleep Disorder; Breathing-Related, Pain
Phase 2CompletedUniversity of California, San Diego622021-08-102024-12-02
Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
AD113, Atomoxetine - Obstructive Sleep Apnea, Hypertension
Phase 2CompletedApnimed212021-07-312023-08-21
A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea
BAY2586116, Placebo - Sleep Apnea, Obstructive
Phase 2CompletedBayer932021-03-032022-10-26
AD109 Dose Finding in Mild to Moderate OSA
AD109 dose1- A, AD109 dose2- B, Placebo- C - Obstructive Sleep Apnea
Phase 2CompletedApnimed322020-12-222022-12-22
Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
AD036, Placebo - Sleep Disordered Breathing
Phase 2CompletedBrigham and Women's Hospital532020-12-022022-03-02

Showing 20 of 107. Sign in to see all of them.

Narrower conditions

Sleep Apnea, Obstructive (75)  ·  Sleep Apnea Syndromes (45)  ·  Hypertension (10)  ·  Obesity (6)  ·  Sleep Wake Disorders (6)  ·  Sleep Apnea, Central (4)  ·  Stroke (4)  ·  Diabetes Mellitus (3)  ·  Pain (3)  ·  Sleep Initiation and Maintenance Disorders (3)  ·  Cardiovascular Diseases (2)  ·  Chronic Pain (2)  ·  Disorders of Excessive Somnolence (2)  ·  Ischemic Attack, Transient (2)

Broader conditions

Respiratory Tract Diseases (107)  ·  Respiration Disorders (105)  ·  Dyssomnias (104)  ·  Nervous System Diseases (104)  ·  Sleep Disorders, Intrinsic (104)  ·  Sleep Wake Disorders (98)  ·  Sleep Apnea Syndromes (59)  ·  Pathological Conditions, Signs and Symptoms (26)  ·  Signs and Symptoms (23)  ·  Vascular Diseases (15)  ·  Cardiovascular Diseases (14)  ·  Neurologic Manifestations (11)  ·  Mental Disorders (10)  ·  Nutritional and Metabolic Diseases (10)

Interventions

Continuous Positive Airway Pressure (12)  ·  Atomoxetine Hydrochloride (8)  ·  Acetazolamide (6)  ·  Eszopiclone (4)  ·  oxybutynin (3)  ·  Desipramine (2)  ·  Dronabinol (2)  ·  Occlusal Splints (2)  ·  Oxygen (2)  ·  (Lys-Gly)(5)cyclo(75-82)MBP(74-85) (1)  ·  4-Aminopyridine (1)  ·  Adrenergic beta-Antagonists (1)  ·  Allopurinol (1)  ·  Analgesics, Opioid (1)  ·  Atorvastatin (1)

Sponsors

Brigham and Women's Hospital (15)  ·  Apnimed (10)  ·  University of California, San Diego (6)  ·  VA Office of Research and Development (6)  ·  Johns Hopkins University (4)  ·  Bayer (3)  ·  Apnex Medical, Inc. (2)  ·  Göteborg University (2)  ·  Istituto Auxologico Italiano (2)  ·  University of Michigan (2)  ·  University of Washington (2)  ·  Yale University (2)  ·  5i Sciences, Inc. (1)  ·  American University of Beirut Medical Center (1)  ·  ApniCure, Inc. (1)

Countries

United States (70)  ·  Australia (7)  ·  France (4)  ·  Italy (4)  ·  Canada (3)  ·  Germany (3)  ·  Switzerland (3)  ·  United Kingdom (3)  ·  Spain (2)  ·  Sweden (2)  ·  Belgium (1)  ·  Brazil (1)  ·  China (1)  ·  Denmark (1)  ·  Finland (1)

Top investigators

Scott A Sands, PhD (4)  ·  Bradley A Edwards, PhD (3)  ·  Carl J Stepnowsky, PhD (3)  ·  Christopher Schmickl, MD, PhD (2)  ·  Dawn M Bravata, MD (2)  ·  Elisa Perger, MD (2)  ·  Jan Hedner, MD. Prof. (2)  ·  Jeremy Orr, MD (2)  ·  Ron Farkas, MD (2)  ·  Abdulghani Sankari, MD PhD (1)  ·  Alan R Schwartz, M.D. (1)  ·  Alexandra Kearson, BA (1)  ·  Andrew Wellman, MD PhD (1)  ·  Andrew Wellman, MD, PhD (1)  ·  Anne Monique Nuyt, MD (1)

Results publications

PMID 39688178, PMID 12105286, PMID 12126214, PMID 15112907, PMID 17294232, PMID 17441783, PMID 17513285, PMID 18513353, PMID 18711110, PMID 19122865, PMID 21306949, PMID 21801857, PMID 21885958, PMID 21886365, PMID 22043118, PMID 22131599, PMID 22334806, PMID 22547887, PMID 22572632, PMID 22893765, PMID 22968110, PMID 24458967, PMID 24815497, PMID 24918372, PMID 25136550, PMID 25268234, PMID 25770408, PMID 25805361, PMID 25892349, PMID 26210388, PMID 26643404, PMID 26967681, PMID 27092703, PMID 27110692, PMID 28364504, PMID 28387543, PMID 29035093, PMID 29065955, PMID 29121334, PMID 29510792, PMID 29602814, PMID 29718281, PMID 29750475, PMID 29800001, PMID 29800466, PMID 30325462, PMID 30395486, PMID 31119695, PMID 31922899, PMID 32649638

NIH funding

K23HL151880 (2), 1IK2CX000547 (1), 2009 (1), 2015 (1), 2017 (1), 2019 (1), R01HL065176 (1), R01HL084139 (1), R01HL106410 (1), R01HL128658 (1), R01HL146697 (1), R01NS042698 (1), R03HL138068 (1), R61HL151254 (1), U01HL105365 (1)